Provided is a novel bacteriophage CJ20 (KCCM11362P). In addition, the present invention relates to an antibacterial composition including the bacteriophage CJ20 (KCCM11362P) as an active ingredient. Further, the present invention is a method of preventing and/or treating infectious diseases by enterotoxigenic Escherichia coli in animals except for humans using the bacteriophage CJ20 (KCCM11362P) or the antibacterial composition containing the bacteriophage CJ20 (KCCM11362P) as an active ingredient.

A composition comprising at least two different strains of isolated bacteriophages, each capable of infecting a bacteria of the species Staphylococcus aureus, wherein at least one of said at least two different strains of isolated bacteriophages has a genomic nucleic acid sequence at least 90% identical to one of the nucleic acid sequence as set forth in SEQ ID NOs: 1-7. Uses thereof are also disclosed.

The system described herein for bacterial identification can be used as a point-of-care or lab-based diagnostic system. In some implementations, the system can be used to detect other foreign agents within blood or other samples. The system can include disposable microfluidic cartridges that are removable from the system. The microfluidic cartridges can receive a sample, such as a blood sample, that is suspected of containing bacterial cells and separate the bacterial cells from the blood sample. Once the bacterial cells are separated from the blood, the system can introduce the recombinant detector bacteriophages into the system that can infect the bacterial cells. The system can then detect the expression of reporter genes from the recombinant detector bacteriophages.

The present invention relates to novel bacteriophages specific to Klebsiella pneumoniae strains, and compositions comprising the same. Particularly, polypeptides and their coding nucleic acid molecule of the novel bacteriophages are provided. The invention also relates to applications of the novel bacteriophages and the polypeptides in the detection/treatment/prevention of infection caused by Klebsiella pneumoniae strains. Development of immunogen and vaccine on the basis of the polypeptides are also provided.

Provided is a novel bacteriophage CJ19 (KCCM11361P). In addition, the present invention relates to an antibacterial composition including the bacteriophage CJ19 (KCCM11361P) as an active ingredient. Further, the present invention is a method of preventing and/or treating infectious diseases by enterotoxigenic Escherichia coli in animals except for humans using the bacteriophage CJ19 (KCCM11361P) or the antibacterial composition containing the bacteriophage CJ19 (KCCM11361P) as an active ingredient.

The present invention relates to novel bacteriophages specific to Klebsiella pneumoniae strains, and compositions comprising the same. Particularly, polypeptides and their coding nucleic acid molecule of the novel bacteriophages are provided. The invention also relates to applications of the novel bacteriophages and the polypeptides in the detection/treatment/prevention of infection caused by Klebsiella pneumoniae strains. Development of immunogen and vaccine on the basis of the polypeptides are also provided.

The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Escherichia coli strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.

Bacteriophages that comprise a tail fiber protein sequence comprising a C terminus host recognition site described by SEQ ID NO: 1 and which infect Ralstonia solanacearum which causes bacterial wilt disease are disclosed. Compositions comprising these bacteriophages may be employed as wilt control agents. Methods for preventing or treating diseases caused by Ralstonia solanacearum such as bacterial wilt disease are also disclosed. A bacterial wilt disease control method in a plant may include administering such bacteriophages to a plant or to a plant growth medium and can be effective against a wide variety of Ralstonia solanacearum strains. Nucleic acids encoding the C terminus host recognition site and amino acid sequences comprising the host recognition site are also disclosed.

The present disclosure relates to CRISPR-Cas10 systems and methods for phage genome editing.

A carbomer hydrogel for maintaining the natural skin microflora and suppressing pathogenic bacteria that contains lytic enzymes and/or highly stable crude/purified Staphylococcus aureus phage lysates with a titer of at least 10.sup.7 pfu/g of gel and crude/purified Cutibacterium acnes phage lysates with a titer of at least 10.sup.5 pfu/g of gel.